Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Low Dose Regular insulin Clear all
Withdrawn No phase listed Observational

A Quality of Life Study Using Insulin Potentiation Targeted LowDose (IPTLD) Chemotherapy and Nutrition Therapy in the Treatment of Cancer

NCT02598479
View directory record Official record
Conditions
Cancer
Interventions
IPTLD and nutrition therapy
Other
Lead sponsor
Best Answer for Cancer Foundation
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 27, 2026, 1:19 PM EDT
Withdrawn Not applicable Interventional

Low Dose Growth Hormone in Obese PCOS Women

NCT00518635
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Nutropin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 27, 2026, 1:19 PM EDT
Completed No phase listed Observational

Specialized Technology Education for Pumps & Pens in Underserved Populations With Diabetes

NCT04550585
View directory record Official record
Conditions
Type1diabetes
Interventions
Education: Session 1 - Basics of type 1 management, Session 2 - Carbohydrate counting, Education: Session 3 - Insulin self- adjustment, Education: Session 4 - Sick day rules and physical activity dose adjustments, Education: Session 5 - Starting the insulin pen (for pen users) or pump (for pump users), Education: Session 6 - Trouble shooting the pump (for pump users)
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 75 Years
Enrollment
63 participants
Timeline
2017 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Not applicable Interventional

Resistant Starch on Glucose and Insulin Sensitivity in Individuals With Type 2 Diabetes

NCT00691249
View directory record Official record
Conditions
Hyperglycemia
Interventions
Resistant Starch Type 4-Raw, Resistant Starch Type 4-Cooked, Shredded Wheat
Dietary Supplement
Lead sponsor
Kansas State University
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2009 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Results available

Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)

NCT02580591
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
977 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
39
States / cities
Montgomery, Alabama • Concord, California • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Correction of Vitamin D Levels and Its Effect on Insulin Resistance and Weight Gain in Obese Youth

NCT02168660
View directory record Official record
Conditions
Obesity, Insulin Resistance, Vitamin D Deficiency
Interventions
Vitamin D3
Drug
Lead sponsor
Perrin C White, MD
Other
Eligibility
6 Years to 17 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 27, 2026, 1:19 PM EDT
Recruiting Phase 3 Interventional

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

NCT07754461
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Placebo, Survodutide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
89
States / cities
Birmingham, Alabama • Gilbert, Arizona • Paradise Valley, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Phase 4 Interventional Results available

Inpatient Diabetes on Corticosteroids

NCT01970241
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
NPH, Correction Factor
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years to 79 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Early Phase 1 Interventional

Low Dose Growth Hormone (GH) on Insulin Sensitivity and Cortisol Production Rates

NCT00517062
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Growth hormone (Genotropin), Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

Improving Post-Prandial Blood Glucose Control With Afrezza During Closed-Loop Therapy

NCT03234491
View directory record Official record
Conditions
Post-Prandial Hyperglycemia, Post-Prandial Hypoglycemia
Interventions
DiAS, Afrezza low dose, Afrezza high dose
Device · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Prebiotic Sodas on Satiety and Metabolic Responses in Healthy Men

NCT07105826
View directory record Official record
Conditions
Olipop, Poppi, Coca Cola - Classic, Diet Coke
Interventions
Prebiotic Soda 1, Prebiotic Soda 2, Diet Soda, Regular Coke
Other
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes

NCT02866435
View directory record Official record
Conditions
Hypoglycemia
Interventions
Insulin, Glucose, Potassium phosphate
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Phase 3 Interventional

Islet Transplantation in Type 1 Diabetes

NCT00434811
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Antithymocyte Globulin, Sirolimus, Tacrolimus, Etanercept, Islet Transplantation, Basiliximab
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Sep 27, 2026, 1:19 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Measurement of Insulin Levels in Cerebral Spinal Fluid (CSF) of Healthy Adults After a Single Intranasal Dose

NCT05866367
View directory record Official record
Conditions
Healthy
Interventions
Low dose Regular Insulin, High dose Regular insulin
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 35 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Not applicable Interventional

Resveratrol-Leucine Metabolite Synergy in Pre-diabetes

NCT01593605
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Resveratrol, resveratrol /HMB, Placebo treatment
Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Low-Dose Baclofen Administration on the GH-IGF1 Axis Study

NCT00871455
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Baclofen
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
20 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2012 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Low Dose Fat-Induced Insulin Resistance

NCT03479671
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Resistance, Insulin Sensitivity
Interventions
Intralipid, 20% Intravenous Emulsion
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 44 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 27, 2026, 1:19 PM EDT
Active, not recruiting Not applicable Interventional

Insulin Detemir in Obesity Management

NCT01239550
View directory record Official record
Conditions
Diabetes, Obesity
Interventions
Detemir
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
31 Years to 60 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 27, 2026, 1:19 PM EDT
No Longer Available No phase listed Expanded access

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

NCT01049633
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Sirolimus, Basiliximab, Tacrolimus, Antibacterial, Antifungal, and Antiviral Prophylaxis, Trimethoprim/sulfamethoxazole, Clotrimazole, Valganciclovir, Heparin, Enoxaparin, Pentoxifylline, Aspirin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Sep 27, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional Results available

Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency

NCT04588688
View directory record Official record
Conditions
Central Adrenal Insufficiency, Mifepristone
Interventions
Mifepristone
Drug
Lead sponsor
Tobias Else
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Not applicable Interventional

Technological Advances in Glucose Management in Older Adults

NCT03078491
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Older Adults, Hypoglycemia
Interventions
eCGM (enhanced CGM)
Other
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
65 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

NCT01306214
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Placebo, BI 10773
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
26
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Understanding Dose Related Effects of Strawberry

NCT06173765
View directory record Official record
Conditions
Pre-diabetes, Insulin Sensitivity, Insulin Resistance, Inflammation
Interventions
freeze-dried whole strawberry powder 36 g powder, freeze-dried whole strawberry powder 12 g, freeze-dried control powder 0 g strawberry
Other
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
20 Years to 60 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 27, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

NCT01011868
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773 placebo, BI 10773 low dose, BI 10773 high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Sep 27, 2026, 1:19 PM EDT